At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 105 enrolled
Drug / intervention
Fluticasone Propionate +2 moredrug
Likely dose
Fluticasone Propionate 250 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effects of Montelukast on Sputum Cells and Inflammatory Markers in Smokers With Asthma
In Brief
A Phase 4 clinical trial evaluating Fluticasone Propionate, Montelukast, and 1 other intervention for Asthmatic Smokers and Non-asthmatic Smokers. Completed, enrolled 105 participants across 1 site.
Detailed Summary
The purpose of this study is: 1. To compare neutrophilia, eosinophilic inflammatory markers and asthma symptom indices between smokers and non-smokers. 2. To elucidate the mechanism by which cigarette smokers are resistant to corticosteroids.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthmatic Smokers, Non-asthmatic Smokers
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedJul 2008
Primary CompletionMay 2011
TodayJul 2026
First PostedJul 9, 2008
Enrollment StartFeb 1, 2007
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 18.0 years ago
Interventions
Fluticasone Propionatedrug
DPI 250 mcg BID for 3 weeks
Montelukastdrug
PO 10 mg QHS for 3 weeks
Salmeteroldrug
DPI 50mg BID for 3 weeks